HumanexaHumanexaHumanexa
WelcomeSignalsCompaniesAssetsScenario AnalysisRegulatoryStrategy
InsightsNewslettersReportsBriefings
Pricing
WorkspaceTeamWatchlistsCollectionsSettings

Free

Intelligence Active

Cardiology · Diabetes Competitive Landscape

Intelligence report

Intelligence Report · ~14 min read

Cardiology · Diabetes Competitive Landscape

23 findings · 154 signals · 20 insights

Type

Competitive Landscape Report

Generated

Jul 23, 2026

Confidence

Moderate Confidence · 83%

Evidence

177 items

Sources

4

Executive Summary

Synthesized assessment from linked signals, findings, and evidence relationships.

Competitive landscape assessment for Cardiology · Diabetes synthesizes 23 Competitiva findings across 154 active signals. 7 high-pressure competitive threats identified. 8 companies maintain material exposure in this therapeutic area.

Key Developments

Material intelligence events ranked by strategic relevance.

  1. competitive

    Pfizer — QTERN

    Pfizer is a regulatory competitive threat because recent agency-facing activity on QTERN in Diabetes · SGLT2 Inhibitor / DPP-4 Inhibitor may reset approval benchmarks and timeline expectations for AstraZeneca.

    View detail
  2. competitive

    Pfizer — STEGLUJAN

    Pfizer is a direct competitive threat because it is already approved in Diabetes · SGLT2 Inhibitor / DPP-4 Inhibitor (STEGLUJAN) and could narrow Merck's development lead.

    View detail
  3. competitive

    Pfizer — STEGLATRO

    Pfizer is a regulatory competitive threat because recent agency-facing activity on STEGLATRO in Diabetes · SGLT2 Inhibitor may reset approval benchmarks and timeline expectations for Merck.

    View detail
  4. competitive

    Pfizer — Farxiga

    Pfizer is a regulatory competitive threat because recent agency-facing activity on Farxiga in Diabetes · SGLT2 Inhibitor may reset approval benchmarks and timeline expectations for AstraZeneca.

    View detail
  5. competitive

    Pfizer — Mounjaro

    Pfizer is a direct competitive threat because it has a development-stage program in Diabetes · GLP-1 (Mounjaro) and could narrow Lilly's development lead.

    View detail
  6. competitive

    Roche — Mounjaro

    Roche is a direct competitive threat because it has a development-stage program in Diabetes · GLP-1 (Mounjaro) and could narrow Lilly's development lead.

    View detail
  7. competitive

    Roche — Mounjaro

    Roche is a direct competitive threat because it has a development-stage program in Diabetes · GLP-1 (Mounjaro) and could narrow Lilly's development lead.

    View detail
  8. competitive

    Pfizer — Pipeline activity

    Pfizer is an emerging emerging competitor with development-stage activity on Pipeline activity in Diabetes · GLP-1 Receptor Agonist; while behind Lilly (development-stage), accelerated readouts could compress Lilly's strategic window.

    View detail
  9. competitive

    Roche — Pipeline activity

    Roche is an emerging emerging competitor with Phase III activity on Pipeline activity in Diabetes · GLP-1 Receptor Agonist; while behind Lilly (development-stage), accelerated readouts could compress Lilly's strategic window.

    View detail
  10. competitive

    Roche — Pipeline activity

    Roche is an emerging emerging competitor with Phase III activity on Pipeline activity in Diabetes · GLP-1 Receptor Agonist; while behind Lilly (development-stage), accelerated readouts could compress Lilly's strategic window.

    View detail
  11. competitive

    Roche — AZD5004

    Roche is a regulatory competitive threat because recent agency-facing activity on AZD5004 in Diabetes · Drug Interaction may reset approval benchmarks and timeline expectations for AstraZeneca.

    View detail
  12. competitive

    Roche — AZD5004

    Roche is a regulatory competitive threat because recent agency-facing activity on AZD5004 in Diabetes · Drug Interaction may reset approval benchmarks and timeline expectations for AstraZeneca.

    View detail

Strategic Implications

Portfolio and competitive decisions informed by this intelligence profile.

Monitor 7 high-pressure competitive programs for portfolio displacement risk. Cross-reference 20 executive insights for synthesized strategic assessment. Leading competitive pressure: Medium across top-linked programs.

Supporting Evidence

Evidence-backed items with source attribution and confidence disclosure.

  • Pfizer — QTERN

    95%

    Pfizer is a regulatory competitive threat because recent agency-facing activity on QTERN in Diabetes · SGLT2 Inhibitor / DPP-4 Inhibitor may reset approval benchmarks and timeline expectations for AstraZeneca.

    Source: Pfizer

    View evidence

  • Pfizer — STEGLUJAN

    79%

    Pfizer is a direct competitive threat because it is already approved in Diabetes · SGLT2 Inhibitor / DPP-4 Inhibitor (STEGLUJAN) and could narrow Merck's development lead.

    Source: Pfizer

    View evidence

  • Pfizer — STEGLATRO

    90%

    Pfizer is a regulatory competitive threat because recent agency-facing activity on STEGLATRO in Diabetes · SGLT2 Inhibitor may reset approval benchmarks and timeline expectations for Merck.

    Source: Pfizer

    View evidence

  • Pfizer — Farxiga

    95%

    Pfizer is a regulatory competitive threat because recent agency-facing activity on Farxiga in Diabetes · SGLT2 Inhibitor may reset approval benchmarks and timeline expectations for AstraZeneca.

    Source: Pfizer

    View evidence

  • Pfizer — Mounjaro

    68%

    Pfizer is a direct competitive threat because it has a development-stage program in Diabetes · GLP-1 (Mounjaro) and could narrow Lilly's development lead.

    Source: Pfizer

    View evidence

  • Roche — Mounjaro

    75%

    Roche is a direct competitive threat because it has a development-stage program in Diabetes · GLP-1 (Mounjaro) and could narrow Lilly's development lead.

    Source: Roche

    View evidence

  • Roche — Mounjaro

    75%

    Roche is a direct competitive threat because it has a development-stage program in Diabetes · GLP-1 (Mounjaro) and could narrow Lilly's development lead.

    Source: Roche

    View evidence

  • Pfizer — Pipeline activity

    74%

    Pfizer is an emerging emerging competitor with development-stage activity on Pipeline activity in Diabetes · GLP-1 Receptor Agonist; while behind Lilly (development-stage), accelerated readouts could compress Lilly's strategic window.

    Source: Pfizer

    View evidence

  • Roche — Pipeline activity

    74%

    Roche is an emerging emerging competitor with Phase III activity on Pipeline activity in Diabetes · GLP-1 Receptor Agonist; while behind Lilly (development-stage), accelerated readouts could compress Lilly's strategic window.

    Source: Roche

    View evidence

  • Roche — Pipeline activity

    74%

    Roche is an emerging emerging competitor with Phase III activity on Pipeline activity in Diabetes · GLP-1 Receptor Agonist; while behind Lilly (development-stage), accelerated readouts could compress Lilly's strategic window.

    Source: Roche

    View evidence

  • Roche — AZD5004

    82%

    Roche is a regulatory competitive threat because recent agency-facing activity on AZD5004 in Diabetes · Drug Interaction may reset approval benchmarks and timeline expectations for AstraZeneca.

    Source: Roche

    View evidence

  • Roche — AZD5004

    85%

    Roche is a regulatory competitive threat because recent agency-facing activity on AZD5004 in Diabetes · Drug Interaction may reset approval benchmarks and timeline expectations for AstraZeneca.

    Source: Roche

    View evidence

  • Roche — AZD5004

    85%

    Roche is a regulatory competitive threat because recent agency-facing activity on AZD5004 in Diabetes · Drug Interaction may reset approval benchmarks and timeline expectations for AstraZeneca.

    Source: Roche

    View evidence

  • Roche — AZD5004

    85%

    Roche is a regulatory competitive threat because recent agency-facing activity on AZD5004 in Diabetes · Drug Interaction may reset approval benchmarks and timeline expectations for AstraZeneca.

    Source: Roche

    View evidence

  • Roche — AZD5004

    85%

    Roche is a regulatory competitive threat because recent agency-facing activity on AZD5004 in Diabetes · Drug Interaction may reset approval benchmarks and timeline expectations for AstraZeneca.

    Source: Roche

    View evidence

  • Roche — Pipeline activity

    85%

    Roche is an emerging emerging competitor with Phase II activity on Pipeline activity in Diabetes · Pharmacokinetics; while behind Merck (Phase II), accelerated readouts could compress Merck's strategic window.

    Source: Roche

    View evidence

Related Intelligence

Deep links to signals, insights, companies, and assets in the Humanexa graph.

Signals

  • FDA Approves Supplemental Application for QTERN (Dapagliflozin/Saxagliptin)

    Regulatory Approval

  • Lilly Q1 2026 Revenue Up 56%, Raises Full Year Guidance

    Pipeline Update

  • FDA Approves First Oral PCSK9 Inhibitor Lipfendra for High Cholesterol

    Regulatory Approval

  • Merck's LIPFENDRA Approved as First Oral PCSK9 Inhibitor for Hypercholesterolemia

    Regulatory Approval

  • Medtronic Recalls Harmony Delivery Catheter Due to Detachment Risk

    Safety Signal

  • AstraZeneca's Dapagliflozin Approved for Heart Failure; Real-World Study Launched in Germany

    Regulatory Approval

  • FDA Approves Supplemental Application for BRILINTA (Ticagrelor)

    Regulatory Approval

  • FDA Accepts BLA for Langlara by Sunshine Lake Pharma

    Regulatory Approval

Insights

  • Lilly's Revenue Surge Signals Competitive Shift in GLP-1 Market

    Diabetes · GLP-1

  • Strategic Implications of Lipfendra's Approval as First Oral PCSK9 Inhibitor

    Cardiology · Cholesterol Management

  • Merck's LIPFENDRA Approval Reshapes Hypercholesterolemia Treatment Landscape

    Cardiology · Hypercholesterolemia

  • AstraZeneca's Dapagliflozin Approval Enhances Competitive Position in Heart Failure Market

    Cardiology · Heart Failure

  • Emerging Competitive Threat in Continuous Glucose Monitoring Market from SAVA Technologies

    Diabetes · Continuous Glucose Monitoring

  • Insulet's Omnipod Recall: Strategic Risks and Competitive Dynamics in Insulin Delivery

    Diabetes · Insulin Delivery

  • Mobile Technology's Potential to Transform Cardiac Rehabilitation Post-ACS

    Cardiology · Rehabilitation

  • Sanofi's Venglustat Trial: A Potential Game Changer in Fabry Disease Treatment

    Cardiology · Fabry Disease

Companies

  • Merck

    132 signals

  • AstraZeneca

    127 signals

  • Eli Lilly

    78 signals

  • Novartis

    38 signals

  • Janssen

    36 signals

  • GSK

    16 signals

  • Teva

    25 signals

  • Sandoz

    27 signals

PrivacyTermsRefund PolicyDisclaimerContact

© 2026 Humanexa. Intelligence for research workflows — not medical, legal, regulatory filing, or investment advice.